Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Chlodantane

Our opinion on this compoundSingle-lab provenance

38/100

Obscure Soviet actoprotector with unique structure but zero human data and single-lab preclinical base

Look, chlodantane is the kind of compound that sits at the intersection of genuine scientific interest and deeply frustrating evidence gaps. Developed at the Zakusov State Institute of Pharmacology during a systematic SAR campaign that screened 329 adamantane derivatives for actoprotector activity, ADK-910 emerged as one of two lead compounds alongside bromantane. The key structural difference: where bromantane carries an arylamine linkage, chlodantane uses a para-chlorobenzoyl amide. On paper, that substitution produces a different pharmacological profile, including what the Morozov group reported as more pronounced immunostimulant activity in rodent stress models.

The multi-mechanism story is what we find genuinely interesting here. Membrane stabilization, lipid peroxidation suppression, immunomodulatory activity, and possible dopaminergic involvement is a composite profile that doesn’t map cleanly onto most other actoprotectors. Bemitil and adapromine work through different, often less-characterized pathways; bromantane’s dopaminergic angle is better documented but its immunostimulant properties are weaker by comparison. If you’re specifically trying to interrogate the relationship between structural variation in the adamantane scaffold and divergent pharmacological output, chlodantane is actually a useful structural probe.

But here’s the thing: the evidence base is almost entirely single-lab preclinical. The Zakusov Institute ran serious pharmacology, not pseudoscience, but the chlodantane data was never independently replicated. No multi-lab confirmation. No clinical studies. Not even a phase 1. Bromantane made it to registration in Russia as Ladasten for neurasthenia; chlodantane didn’t clear the threshold for advancement. That asymmetry tells you something about where the Morozov group’s own priorities landed, and it should inform yours.

What we dont like is the zero translational signal. The actoprotector class, broadly, has shown frustratingly little in the way of strong human data even for compounds like bemitil that carry decades of Soviet-era clinical use claims. Chlodantane is further back than bemitil on every dimension of human evidence. If your research program cares about bench-to-clinic arrows, there isnt one here. Sourcing is an additional practical obstacle: no commercial peptide or research chemical vendor stocks this routinely, and synthesis from 2-aminoadamantane is feasible but adds friction most programs don’t want.

What we do like is the unique structural position within the adamantane actoprotector class. For investigators studying physical performance pharmacology, synthetic adaptogen SAR, or membrane-active small molecules with secondary immunostimulant properties, chlodantane occupies a genuine niche as a comparator. It’s just a narrow niche. The compound works best as supporting context in a broader adamantane SAR program, not as a primary research target. A serious research program would almost certainly run bromantane or bemitil first, and treat chlodantane as one data point in a structural series rather than a headline compound worth dedicated resources.

Novelty

60

Mechanism promise

45

In-category differentiation

40

Evidence quality

20

Translational signal

17

Research bench value

38

Rationale Chlodantane scores on structural novelty within the adamantane class and a genuinely composite multi-mechanism profile, but is fatally limited by single-lab preclinical evidence from the Zakusov Institute only, no clinical advancement, and no translational signal; bromantane’s clinical registration in Russia as Ladasten makes the asymmetry in development priority clear.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Adamantane-derived actoprotector and synthetic adaptogen with membrane-stabilizing, antioxidant, and immunostimulant activity

An adamantane-derived para-chlorobenzamide developed at the Zakusov State Institute of Pharmacology as a rapid-onset synthetic adaptogen, distinguished from bromantane by a benzoyl (rather than amine) linkage, broader adaptogenic activity spectrum, and more pronounced immunostimulant properties in preclinical models.

Abstract

Chlodantane (ADK-910), the para-chlorobenzoyl amide of 2-aminoadamantane, is an experimental actoprotector and synthetic adaptogen developed at the Zakusov State Institute of Pharmacology of the Russian Academy of Medical Sciences during an extensive structure-activity campaign that screened 329 novel adamantane derivatives for resistance-enhancing properties in rodent stress models [1, 2]. The compound emerged alongside bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) as one of two lead adamantane-derived actoprotectors from the Morozov laboratory program; however, whereas bromantane proceeded to clinical registration in Russia as Ladasten for the treatment of neurasthenia, chlodantane was never advanced to human studies and remains an exclusively preclinical research compound.

Structurally, chlodantane differs from bromantane in the nature of the bond connecting the adamantane cage to the halogenated aromatic ring. Bromantane is a secondary amine (N-(2-adamantyl)-N-(4-bromophenyl)amine), whereas chlodantane is an amide (N-(2-adamantyl)-4-chlorobenzamide), a distinction that alters conformational flexibility, hydrogen-bonding capacity, metabolic susceptibility, and physicochemical behavior [1]. The chlorine-for-bromine halogen substitution is a secondary modification. These combined structural differences produce a pharmacological profile that the primary literature describes as exhibiting a broader adaptogenic activity spectrum than bromantane, with efficacy against hypoxia, hypothermia, hyperthermia, toxic chemical exposure, and other extreme environmental stressors observable after a single administration, a property not characteristic of classical plant-derived adaptogens that typically require repeated dosing over days to weeks [2, 3].

The mechanism of action has not been fully elucidated. The available evidence, derived entirely from animal and cell-culture experiments, points to membrane stabilization as a principal contributor. Chlodantane increases the stability of cell membranes against unfavorable conditions, achieved in part through suppression of overactivated lipid peroxidation (LPO) processes [2, 3]. The adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane skeleton with high lipophilicity, partitions into lipid bilayers and interacts with the polar headgroup region of phospholipid membranes, a property shared across the broader adamantane pharmacological class and formally characterized in molecular dynamics simulations of amantadine and memantine in model bilayers [4, 5]. The immunostimulant activity of chlodantane is reported to be more pronounced than that of bromantane, with efficacy in secondary stress-induced immunodeficiency models, though the molecular targets mediating this effect have not been identified [1, 2].

No human pharmacokinetic, efficacy, or safety data exist for chlodantane. The pharmacokinetic profile is inferred from the structurally related bromantane, which displays moderate oral bioavailability (approximately 42 percent), a plasma elimination half-life of approximately 11 hours, hepatic hydroxylation of the adamantane ring as the principal metabolic pathway, and wide tissue distribution driven by the lipophilicity of the adamantane core [6, 7]. Whether the amide bond in chlodantane introduces additional metabolic liabilities (amide hydrolysis, different ring-hydroxylation regioselectivity) relative to the amine bond in bromantane has not been characterized. The compound is not approved for medical use in any jurisdiction and is not listed on any national pharmacopoeia. It is available as a research-grade preparation from limited specialty chemical suppliers at purities stated as greater than 98 percent. Investigators should obtain independent analytical confirmation of identity, purity, and stereochemical composition on every lot. This monograph reviews the chemistry, synthesis, and structural pharmacology of chlodantane; the available preclinical evidence for adaptogenic, actoprotective, antioxidant, and immunostimulant activity; the inferred pharmacokinetics; sourcing and quality considerations; and a comparative assessment of five actoprotector and adaptogenic candidates against chlodantane on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1545Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
ITPP

Our opinion on this compoundNovel, promising

60/100

First-in-class membrane-permeant hemoglobin allosteric effector with real hypoxia signal but a slow and still-open clinical trajectory

Here’s the thing about ITPP: the core design idea is genuinely elegant. Jean-Marie Lehn’s lab engineered a molecule that does what 2,3-DPG does endogenously but actually gets inside the erythrocyte to do it. Phytic acid can’t cross the red cell membrane. 2,3-DPG can’t either. ITPP can, and that single design decision opens up a class of biology that nobody else is touching with anything comparably clean.

The mechanism runs through the band 3 anion transporter on erythrocyte membranes. Once inside, ITPP occupies the T-state allosteric pocket of deoxyhemoglobin, pulling P50 rightward without wrecking cooperativity or total oxygen-carrying capacity. Thats the critical point. You’re not reducing how much O2 the blood carries. You’re changing where and when it gets released. In hypoxic tissue, that’s exactly the intervention you want.

The preclinical case is solid across multiple indications. In oncology models, rightward shifting the dissociation curve reduces tumor hypoxia, which independently drives resistance to both radiation and chemotherapy. The cardiovascular angle involves improved O2 delivery during ischemia. There’s also a metabolic and anti-adiposity signal in animal work that is harder to fully explain but appears reproducible enough to be interesting. Preclinical breadth is encouraging, even if it raises the question of whether one mechanism can really do all of that.

Clinical development exists but is thin. The Phase 1a healthy volunteer study established tolerability. NCT02528526 is a Phase Ib dose-escalation in cancer patients under the OXY111A development code at Normoxys. We dont have Phase 2 data, and honestly ITPP has been in development for over two decades without a clear clinical win. That’s a real flag. The compound works in animals. Whether a P50 shift is sufficient to move the needle in human oncology, where tumor hypoxia is one problem among many, is genuinely unsettled.

As a bench tool, ITPP is probably underused relative to its probe value. If your program touches hypoxia biology, tumor oxygenation gradients, or the interface between erythrocyte physiology and metabolic signaling, this is the only clean pharmacological handle that modulates erythrocyte O2 release without altering total oxygen capacity. Nothing else does that. WADA’s anti-doping classification confirms that regulatory scientists agree it produces real physiological effects in humans, which is a meaningful external signal.

What we like: the rational design origin, the truly unique mechanistic niche, and the multi-indication preclinical reach. What we don’t like: a slow clinical trajectory heavily concentrated in a single development group, and the open question of whether the P50 shift is sufficient as a monotherapy lever when tumor hypoxia is multifactorial. A legitimately interesting compound at an unsettled research frontier. Not proven, but not noise either.

Novelty

58

Mechanism promise

73

In-category differentiation

72

Evidence quality

40

Translational signal

45

Research bench value

65

Rationale ITPP occupies a genuinely unique pharmacological niche as the only membrane-permeant rightward-shifting allosteric effector of hemoglobin, with rational design provenance from Lehn’s lab and multi-indication preclinical signal, but Phase Ib is the ceiling of the clinical evidence base and a 20-year development timeline without a clear win holds both novelty and translational scores in check.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic membrane-permeant allosteric effector of hemoglobin (inositol pyrophosphate class)

A first-in-class inositol pyrophosphate designed to cross the erythrocyte membrane, reduce hemoglobin oxygen affinity via right-shift of the oxyhemoglobin dissociation curve, and enhance regulated oxygen delivery to hypoxic tissues, with preclinical and early clinical investigation across oncology, cardiovascular, and metabolic indications.

Abstract

Myo-inositol trispyrophosphate (ITPP) is a synthetic pyrophosphate derivative of phytic acid that functions as a membrane-permeant allosteric effector of hemoglobin, reducing the affinity of hemoglobin for oxygen and shifting the oxyhemoglobin dissociation curve to the right, thereby enhancing the release of molecular oxygen from erythrocytes into tissues under conditions of low partial pressure of oxygen. The compound was conceived in the laboratory of Jean-Marie Lehn (Nobel Laureate in Chemistry, 1987) and Claude Nicolau in the early 2000s as a rationally designed analog of the endogenous erythrocyte effector 2,3-diphosphoglycerate (2,3-DPG), engineered to bear three cyclic pyrophosphate rings on the myo-inositol scaffold that confer net negative charge sufficient to bind the positively charged central cavity of deoxyhemoglobin while maintaining membrane permeability across the erythrocyte plasma membrane via the band 3 anion transport complex. Unlike 2,3-DPG and the structurally related phytic acid (inositol hexakisphosphate), which cannot traverse the red blood cell membrane, ITPP enters the erythrocyte intact and engages the allosteric T-state binding site of hemoglobin in situ, producing a dose-dependent rightward shift of the P50 (the partial pressure of oxygen at which hemoglobin is 50 percent saturated) without altering cooperativity or total oxygen-carrying capacity.

The preclinical pharmacology of ITPP spans three principal therapeutic domains. In oncology, ITPP-mediated tumor reoxygenation produces downregulation of hypoxia-inducible factor 1-alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), normalization of tumor vasculature through activation of the endothelial PTEN/AKT signaling axis, and potentiation of subsequent chemotherapy and radiation therapy in rodent models of pancreatic, hepatocellular, colorectal, melanoma, glioblastoma, and rhabdomyosarcoma tumors. In cardiovascular medicine, ITPP treatment in rodent models of myocardial infarction and monocrotaline-induced pulmonary hypertension has produced improved myocardial oxygenation, attenuation of adverse left and right ventricular remodeling, reduction of pulmonary hypertension-related mortality, and dose-dependent increases in maximal exercise capacity of up to 57 percent in normal mice and 63 percent in transgenic mice with severe heart failure. In metabolism, ITPP has demonstrated reduction of adipose tissue accumulation in high-fat-diet rodent models through reversal of adipose tissue hypoxia.

The compound entered clinical development under the designation OXY111A through Normoxys, Inc. A Phase Ib dose-escalation study (NCT02528526) conducted at University Hospital Zurich enrolled 28 patients with advanced hepatopancreatobiliary malignancies and colorectal cancer liver metastases across eight dose levels (1,866 to 14,500 mg/m2 per dose), administered as nine 8-hour intravenous infusions over three weeks. The maximum tolerated dose was established at 12,390 mg/m2. The compound was well tolerated, with the principal treatment-related adverse event being asymptomatic hypercalcemia attributable to calcium chloride in the formulation rather than to the compound itself. Pharmacokinetic analysis demonstrated dose-proportional exposure with a terminal half-life of 1.3 to 3.3 hours, no systemic accumulation, and plasma clearance of 3.1 to 4.8 L/h. Morphological disease stabilization was observed in 52 percent of patients under ITPP monotherapy, and subsequent chemotherapy produced stable disease in 60 percent and partial response in 10 percent. Decreases in circulating angiogenic markers (VEGFA, angiopoietin-1, angiopoietin-2, EGF, PECAM1) were observed in a majority of patients and correlated with improved survival following chemotherapy. ITPP is prohibited in competitive sport by the World Anti-Doping Agency as a substance with potential to enhance oxygen transfer, and analytical methods for its detection in human urine and equine plasma have been developed for anti-doping enforcement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1531Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
PP-405

Our opinion on this compoundNovel, promising

65/100

First-in-class MPC1/MPC2 inhibitor activates hair follicle stem cells via metabolic reprogramming, mechanistically unlike anything in alopecia

Look, the alopecia treatment space has been stuck for decades. Minoxidil works through vasodilation and potassium channel modulation, finasteride and dutasteride block 5-alpha-reductase, the newer topical antiandrogens like clascoterone and pyrilutamide target androgen receptors directly. None of them are talking to stem cells at the metabolic level. PP-405 is something genuinely different, and the mechanism story starts not with pharmacology but with a 2017 Nature Cell Biology paper from the Christofk and Lowry labs at UCLA that reframed how people think about hair follicle stem cell fate.

The Flores et al. finding was this: hair follicle stem cells in the bulge region are glycolytic by preference, producing substantially more lactate than surrounding epidermal populations. Genetic deletion of Ldha in mice prevents HFSC activation entirely. Genetic deletion of Mpc1 accelerates the hair cycle. Thats genetic validation, not pharmacology, and Michael Jung’s group at UCLA treated it as such. They iterated from UK-5099 through a cyano-cinnamate SAR program, optimizing potency and dermal penetration until they had something that could plausibly work as a topical. The result is PP-405, an undisclosed structure with a CAS number that hasn’t been assigned publicly, which is itself a signal that the chemistry is genuinely proprietary.

What we like here is the mechanistic clarity. Blocking MPC1/MPC2 cuts pyruvate import into the mitochondrial matrix, forces the cell toward glycolysis, and upregulates LDH activity, elevating intracellular lactate and pushing quiescent bulge HFSCs toward anagen entry. This isnt receptor agonism in a saturated pharmacological class. There is no equivalent mechanism anywhere in the AGA pipeline, which earns PP-405 a high differentiation score and strong mechanism marks even while the clinical readout remains pending.

Where we temper enthusiasm is on the evidence side. Phase 1 safety and proof-of-mechanism data reportedly exist (NCT06393452 designates Phase 2a, implying Phase 1 preceded it), but no efficacy readout from Phase 2a is publicly available. Dermal delivery at therapeutically relevant concentrations is a real constraint, and AGA has a long history of promising preclinical models that don’t survive the bench-to-clinic translation. The foundational mechanistic work also traces almost entirely back to the Christofk/Lowry/Jung consortium. Independent replication of the core HFSC metabolic phenotype exists in the stem cell biology literature broadly, but the compound-specific pharmacology has not been reproduced outside Pelage’s own program.

For bench investigators studying epithelial stem cell quiescence or the metabolic control of tissue regeneration, PP-405 and the related research compound JXL-069 have real probe value. The MPC1/MPC2 axis is underexplored in non-hepatic tissues, and a potent, topically deliverable inhibitor emerging from a rigorous SAR program is a legitimately useful tool. We think this warrants attention as Phase 2a results emerge. Not a sure thing, but the mechanism is defensible, the target validation is unusually strong for its stage, and nothing else in the space looks like it.

Novelty

72

Mechanism promise

78

In-category differentiation

82

Evidence quality

45

Translational signal

45

Research bench value

55

Rationale PP-405 earns high novelty and differentiation scores as the only clinical-stage MPC inhibitor targeting HFSC metabolic fate, grounded in genetically validated preclinical biology; evidence and translational scores are appropriately tempered because Phase 2a efficacy data has not yet been publicly reported and the entire mechanistic foundation originates from a single UCLA consortium.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-in-class dual mitochondrial pyruvate carrier (MPC1/MPC2) inhibitor for topical hair follicle stem cell activation

A proprietary small-molecule mitochondrial pyruvate carrier inhibitor developed at UCLA and advanced by Pelage Pharmaceuticals as a topical therapy for androgenetic alopecia, distinguished from existing treatments by a first-in-class metabolic mechanism that reactivates quiescent hair follicle stem cells through lactate dehydrogenase upregulation.

Abstract

PP-405 is a first-in-class, topically administered small-molecule inhibitor of the mitochondrial pyruvate carrier (MPC), under clinical development by Pelage Pharmaceuticals for the treatment of androgenetic alopecia (AGA) in men and women. The compound acts as a dual inhibitor of MPC1 and MPC2, blocking pyruvate import into the mitochondrial matrix and thereby redirecting cellular metabolism toward glycolysis with concomitant elevation of intracellular lactate through stimulation of lactate dehydrogenase (LDH) activity. This metabolic shift activates quiescent hair follicle stem cells (HFSCs) residing in the bulge region of the hair follicle, driving telogen-to-anagen transition and the initiation of new hair growth cycles. The mechanistic rationale derives from the seminal Flores et al. (2017) demonstration in Nature Cell Biology that HFSCs utilize glycolytic metabolism, produce substantially more lactate than other epidermal cell populations, and that genetic deletion of lactate dehydrogenase A (Ldha) prevents HFSC activation, while genetic deletion of mitochondrial pyruvate carrier 1 (Mpc1) accelerates the hair cycle in murine models [1]. The medicinal chemistry program at UCLA, led by Michael Jung in collaboration with Heather Christofk and William Lowry, subsequently developed a series of novel MPC inhibitors based on the cyano-cinnamate pharmacophore, advancing from the prototype UK-5099 through iterative structure-activity relationship optimization to produce compounds with markedly enhanced potency and skin-penetration characteristics [2].

PP-405 is the proprietary clinical candidate selected from this program. Its chemical structure has not been publicly disclosed; Pelage Pharmaceuticals has confirmed that PP-405 is structurally distinct from JXL-069, the published 7-azaindole-bearing MPC inhibitor (CAS 2260696-63-5) described in the Jeong et al. (2021) Journal of Medicinal Chemistry report, though both compounds originate from the same UCLA medicinal chemistry effort [2, 3]. The compound has been engineered for preferential skin penetration over systemic absorption, with reported selectivity of approximately 1,000-fold for dermal over plasma distribution. In clinical pharmacokinetic assessments, no PP-405 was detected in circulating blood plasma following topical scalp application at the clinical dose of 0.05%, and the compound is reported to be unstable in blood, providing an intrinsic pharmacokinetic safety margin against systemic exposure [4, 5].

Clinical development has proceeded through a Phase 1 safety and pharmacokinetic study completed in January 2024 and a Phase 2a randomized, multicenter, double-blind, vehicle-controlled efficacy trial (NCT06393452) in 78 adults with androgenetic alopecia. The Phase 1 study demonstrated proof of mechanism through scalp biopsy analysis showing statistically significant upregulation of Ki67-positive proliferating cells in the hair follicle bulge region after seven days of 0.05% PP-405 topical application, with concurrent increases in LDH activity in hair follicle stem cells [4]. Ex vivo human scalp tissue experiments presented at the American Academy of Dermatology 2024 Annual Meeting confirmed that single topical applications of PP-405 at concentrations as low as 0.006% increased LDH activity in HFSCs within 24 hours [4]. The Phase 2a trial reported that 31% of PP-405-treated men with higher-grade hair loss demonstrated greater than 20% increases in hair density at eight weeks following four weeks of daily treatment, compared with 0% in the vehicle-control group; additionally, PP-405 induced new hair growth in areas where no hair was previously present, suggesting regenerative capacity beyond the follicle-preserving activity of existing therapies [5, 6]. The compound was well tolerated with no treatment-related systemic adverse events and no detectable systemic absorption.

Pelage Pharmaceuticals plans to initiate Phase 3 registration trials in 2026 to evaluate the safety and efficacy of PP-405 in both men and women with androgenetic alopecia. If successful, regulatory approval could be anticipated in the 2027 to 2029 timeframe. This monograph reviews the discovery and development history, the metabolic mechanism of action in molecular and cellular detail, the available pharmacokinetic and pharmacodynamic data, the preclinical and clinical evidence base, sourcing and handling considerations for the research-grade precursor compound JXL-069, stack-interaction considerations, adverse-event and safety data, and a comparative assessment of five alternative androgenetic alopecia therapies (minoxidil, finasteride, dutasteride, clascoterone, pyrilutamide) against PP-405 on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1521Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Seltorexant

Our opinion on this compoundNovel, promising

69/100

First selective 2-SORA in Phase 3 for MDD, with a novel HPA axis antidepressant mechanism and clean tolerability story

Look, the orexin story has been building since the late 1990s, and the approved DORAs (suvorexant, lemborexant, daridorexant) have established that blocking orexin receptors is a legitimate path to sleep. What seltorexant does differently is go selective. Its roughly 100-fold preference for OX2R over OX1R isn’t just a cleaner binding profile on paper; it’s what lets researchers actually ask whether OX2R is doing something distinct from OX1R in depression, HPA axis regulation, and the hyperarousal phenotype that shadows so many MDD presentations.

The antidepressant mechanism is what makes this compound genuinely interesting to us. The hypothesis isn’t simply “fix sleep, fix mood.” The OX2R system feeds directly into CRF-mediated HPA activation, and seltorexant’s preclinical attenuation of stress-induced ACTH release in rodents was a meaningful early signal. The Phase 1b data from Recourt et al. (2019) in 47 MDD patients showed HDRS17 improvement at 20 mg over 10-28 days, which for a Phase 1b is a strong translational arrow. That the antidepressant signal held up in Phase 3 MDD3001 with a MADRS least-squares mean difference of negative 2.6 (p = 0.007) adjunctive to SSRI/SNRI is legitimately significant, even if the effect size wont excite anyone trained on GLP-1 trial readouts.

The MDD3005 active comparator trial against quetiapine XR is the more clinically informative data point. Seltorexant didn’t definitively beat quetiapine on response rate (57.4% vs 53.4%, non-significant), but the tolerability gap is real: 6% somnolence versus 24%, and 0.5 kg versus 2.1 kg weight gain over 26 weeks. In a population being asked to take an adjunctive agent long-term, that profile matters to both investigators and eventual prescribers.

What we like about seltorexant as a research target: the short 2-3 hour half-life limits residual confounds in daytime cognition experiments, the OX2R selectivity makes it a cleaner probe than anything previously available in humans, and the monotherapy Phase 1b in 128 patients (2024) suggests the antidepressant signal isn’t entirely dependent on sleep improvement as a mediator. That last point is still being unpacked and represents a real open question worth investigating.

Honestly, the scores here are constrained by what this compound is: an adjunctive antidepressant in a crowded indication with modest-but-real effect sizes. The orexin system itself isn’t new, and the MDD space is not short of mechanistic competitors. what earns its score is the genuine selectivity story, the Phase 3 confirmation, and the Alzheimer’s disease expansion program, which adds a second research rationale worth watching. Not approved yet, but the arc is clear.

Novelty

62

Mechanism promise

72

In-category differentiation

73

Evidence quality

72

Translational signal

68

Research bench value

65

Rationale Seltorexant earns its score through genuine OX2R selectivity that mechanistically separates it from all approved DORAs, confirmed Phase 3 antidepressant efficacy, and real bench utility as the first selective 2-SORA probe in late clinical development; modest MDD effect sizes and a crowded adjunctive antidepressant indication prevent a higher placement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective orexin-2 receptor antagonist (2-SORA) with antidepressant and sleep-promoting activity

A selective orexin-2 receptor antagonist developed by Janssen Pharmaceuticals and Minerva Neurosciences as an adjunctive treatment for major depressive disorder with insomnia symptoms, distinguished from dual orexin receptor antagonists by its high OX2R selectivity, rapid pharmacokinetic profile, and demonstrated antidepressant efficacy through modulation of orexinergic hyperarousal.

Abstract

Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA to advance through Phase 3 clinical trials for major depressive disorder (MDD) with insomnia symptoms. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R and negligible affinity for other receptors, transporters, or ion channels in a panel of 50 assays, a selectivity profile that distinguishes it mechanistically from the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant approved for primary insomnia. Pharmacokinetics are characterized by rapid oral absorption (median time to maximum plasma concentration 0.3 to 1.5 hours), a short elimination half-life of approximately 2 to 3 hours, and metabolism predominantly through cytochrome P450 3A4, producing a pharmacokinetic profile suited to bedtime administration with minimal next-day residual effects. Preclinical pharmacology in rodent models demonstrated dose-dependent increases in non-rapid eye movement (NREM) sleep duration, reduced sleep onset latency, attenuation of stress-induced adrenocorticotropic hormone (ACTH) release, suppression of hypothalamic-pituitary-adrenal (HPA) axis activation, and absence of effects on dopaminergic reward pathways or motor coordination. The specificity of these effects for OX2R was confirmed by the absence of activity in OX2R knockout mice. Brain penetration and receptor occupancy were confirmed by positron emission tomography imaging in rats and by in vivo competitive radioligand binding studies. The clinical evidence base spans Phase 1 through Phase 3 development. The Phase 1b study in 47 patients with MDD (Recourt et al. 2019) demonstrated statistically significant improvement in core depressive symptoms on the Hamilton Depression Rating Scale (HDRS17) and HAM-D6 subscale compared to placebo at 20 mg daily for 10 to 28 days, with concordant changes in sleep electroencephalography spectral power. The Phase 2b adaptive dose-finding study (Savitz et al. 2021) in 283 patients with MDD and inadequate response to SSRI or SNRI therapy reported statistically significant improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score, MADRS-6 core symptom subscale, Insomnia Severity Index, and PROMIS Sleep Disturbance at the 20 mg dose, with response rates of 41.0 percent versus 28.5 percent on placebo and remission rates of 29.5 percent versus 19.0 percent. The pivotal Phase 3 MDD3001 trial achieved its primary and all secondary endpoints, with seltorexant 20 mg adjunctive to SSRI or SNRI producing a statistically significant least-squares mean difference from placebo of negative 2.6 points on MADRS total score at day 43 (p = 0.007) and significant improvement in PROMIS Sleep Disturbance (negative 3.7, p < 0.001). The Phase 3 MDD3005 active-comparator study against quetiapine extended-release demonstrated a numerically higher response rate for seltorexant (57.4 percent versus 53.4 percent) that did not reach statistical significance, but with substantially fewer adverse events, lower somnolence incidence (6 percent versus 24 percent), and markedly less weight gain (0.5 kg versus 2.1 kg over 26 weeks). A separate monotherapy Phase 1b study (2024) in 128 MDD patients demonstrated antidepressant activity independent of adjunctive SSRI or SNRI use. The compound is well tolerated across the clinical program. The most common treatment-emergent adverse events are headache, somnolence, and nausea at incidences comparable to placebo. No deaths, serious treatment-emergent adverse events, clinically significant cardiovascular changes, or suicidal behavior events have been reported in the seltorexant treatment arms. No cataplexy has been observed. The compound does not produce conditioned place preference in mice, does not increase extracellular dopamine release in rat nucleus accumbens, and does not impair motor coordination at sleep-promoting doses, supporting a favorable abuse liability and safety profile relative to benzodiazepines and Z-drugs. Seltorexant has not yet received regulatory approval in any jurisdiction. Phase 3 clinical trials for adjunctive MDD with insomnia symptoms are ongoing, and Phase 2 investigation for primary insomnia and Alzheimer's disease is in progress. This monograph reviews the chemistry, synthesis, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence base, sourcing and handling, stack interactions, adverse-event profile, and a comparative assessment of five orexin receptor antagonist candidates against seltorexant on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1526Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Vadadustat

Our opinion on this compoundEstablished, active research

56/100

FDA-approved HIF-PHI in a now-crowded class; real mechanism, real evidence, modest novelty

Here’s the thing about vadadustat: it’s a real drug doing real biology, and the HIF prolyl hydroxylase inhibitor class it belongs to represents genuinely interesting science. PHD1, PHD2, and PHD3 regulate HIF-alpha stability under normoxic conditions by hydroxylating two conserved proline residues, flagging HIF-alpha for VHL-mediated proteasomal destruction. Vadadustat competes with 2-oxoglutarate at the PHD active site, a cofactor-mimicry approach that prevents hydroxylation and lets HIF-1alpha and HIF-2alpha accumulate even under normal oxygen tension. That’s not just elevated EPO. It’s a coordinated transcriptional response covering transferrin, transferrin receptor, ferroportin, and erythroid progenitor support genes, a more physiological mimic of high-altitude adaptation than the blunt-force pharmacology of injectable ESAs. The biology is worth understanding.

What we like: the FDA approval in 2023 (Vafseo, Akebia Therapeutics) means the clinical evidence base is mature. The INNO2VATE Phase 3 program in dialysis-dependent CKD and PRO2TECT in non-dialysis-dependent CKD give you well-anchored efficacy and safety data. Pharmacokinetics are fully characterized. For anyone studying the HIF axis, iron mobilization, or erythropoiesis regulation, vadadustat is a clean oral probe with a known PK profile and fully annotated mechanism at the PHD active site. The all-three-isoform inhibitory profile with low-nanomolar constants is well-described in the Akebia-era literature under the development code AKB-6548.

What we dont love: there are now five or six compounds in this class pursuing the same indication with mechanistically similar approaches. Roxadustat (FG-4592) was approved in Japan and the EU first; daprodustat (Jesduvroq) received FDA approval around the same window. The differentiation story within the HIF-PHI class is real but modest. Vadadustat’s all-isoform inhibition is clean, but thats not dramatically distinct from daprodustat or molidustat. If your bench question is specifically about PHD isoform contribution to HIF biology, you’d want to compare it against more isoform-selective tool compounds, which is an active area of academic tool chemistry that vadadustat itself doesn’t fully address.

The broader opportunity is the one that gets undersold in the CKD-anemia framing. PHD inhibition and HIF stabilization are relevant to ischemic preconditioning, anti-inflammatory signaling, metabolic reprogramming, and tumor microenvironment biology. Vadadustat as a reference HIF stabilizer for any of those programs is a defensible research use case, and approved-drug status means the safety and toxicology profile is documented in a way that many research compounds can’t match. We think the HIF-PHI class as a whole remains underdeveloped outside the erythropoiesis indication, and vadadustat is a reasonable starting tool if your question lives there. Just don’t expect it to be the only arrow in that quiver.

Novelty

42

Mechanism promise

60

In-category differentiation

38

Evidence quality

73

Translational signal

75

Research bench value

60

Rationale Vadadustat earned FDA approval through serious Phase 3 programs (INNO2VATE, PRO2TECT) and the HIF prolyl hydroxylase mechanism is genuinely interesting biology, but five-plus competitors with similar mechanisms have arrived in parallel, and the class has matured from novel to established faster than most. Bench value holds up as a HIF-axis probe, but differentiation within the HIF-PHI category is the primary score suppressor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) targeting PHD1, PHD2, and PHD3

An oral 2-oxoglutarate-competitive inhibitor of prolyl-4-hydroxylase domain enzymes developed by Akebia Therapeutics for the treatment of anemia due to chronic kidney disease, distinguished from erythropoiesis-stimulating agents by its mechanism of stabilizing hypoxia-inducible factor to coordinate endogenous erythropoietin production, iron mobilization, and erythroid progenitor maturation.

Abstract

Vadadustat (AKB-6548; marketed as Vafseo) is an orally bioavailable small molecule inhibitor of the three human prolyl-4-hydroxylase domain (PHD) isoforms (PHD1, PHD2, PHD3) that regulate the oxygen-sensing hypoxia-inducible factor (HIF) pathway. By competitively displacing the endogenous cofactor 2-oxoglutarate from the PHD active site, vadadustat prevents the hydroxylation and subsequent proteasomal degradation of HIF-alpha subunits, thereby stabilizing HIF-1alpha and HIF-2alpha and activating transcription of erythropoietin, transferrin, transferrin receptor, ferroportin, and other genes that coordinate erythropoiesis and iron homeostasis. The compound was developed by Akebia Therapeutics (Cambridge, Massachusetts) as an alternative to injectable erythropoiesis-stimulating agents (ESAs) for the management of anemia associated with chronic kidney disease (CKD). Vadadustat inhibits all three PHD isoforms with similar low-nanomolar inhibitory constants, and PHD inhibition is competitive with 2-oxoglutarate and insensitive to ambient iron concentration. In preclinical models, a single oral dose in rats potently increased circulating erythropoietin, and daily dosing for 14 days increased red blood cell indices in both healthy rats and the 5/6 nephrectomy model of CKD. In mice and dogs, once-daily repeat oral dosing increased hemoglobin and hematocrit without detectable stimulation of vascular endothelial growth factor.

The clinical development program comprised the global Phase 3 INNO2VATE trials in dialysis-dependent CKD and the PRO2TECT trials in non-dialysis-dependent CKD, both comparing vadadustat to darbepoetin alfa. In the INNO2VATE program, vadadustat met the prespecified noninferiority criteria for both hematologic efficacy and cardiovascular safety. In the PRO2TECT program, vadadustat met the noninferiority criterion for hematologic efficacy but did not meet the noninferiority criterion for cardiovascular safety, with signals of increased major adverse cardiovascular events (MACE), stroke, and hepatic injury relative to darbepoetin alfa. The United States Food and Drug Administration issued a complete response letter in March 2022 citing cardiovascular and hepatotoxicity concerns. Following review of additional post-marketing safety data from Japan (where Vafseo was approved in 2020) and the clinical trial database, the FDA approved vadadustat in March 2024 for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. The approved labeling carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, and the compound is explicitly not indicated for non-dialysis CKD patients.

Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 3 to 4 hours in healthy volunteers, 5 to 6 hours in CKD patients), high plasma protein binding (greater than 99 percent), dose-proportional exposure over a wide dose range, and hepatic glucuronidation as the principal metabolic pathway. The elimination half-life is approximately 4.5 hours in healthy volunteers and extends to 7 to 9 hours in patients with advanced CKD. The compound is a potent inhibitor of the breast cancer resistance protein (BCRP) transporter and a moderate inhibitor of organic anion transporting polypeptide 1B1/1B3 (OATP1B1/1B3), with clinically relevant drug-drug interaction potential for substrates of these transporters. This monograph reviews the chemistry, synthesis, and structural class of vadadustat; the molecular pharmacology of PHD inhibition and HIF stabilization; the comprehensive pharmacokinetic profile; preclinical pharmacology in rodent and canine models; the clinical evidence base from Phase 2 and Phase 3 programs; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative HIF-PHI compounds (roxadustat, daprodustat, molidustat, desidustat, enarodustat) against vadadustat on five standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1499Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Tianeptine

Plain-language summaryIntrigue 70 / 100

Tianeptine is a French-developed atypical antidepressant that, unusually, also activates the mu-opioid receptor. It has anxiolytic and mood-elevating effects but the opioid activity creates dependence and withdrawal at high doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

50/100

MOR-reclassified atypical antidepressant with real neuroplasticity signal but serious abuse liability headwinds

Look, tianeptine is one of the more genuinely weird compounds in the antidepressant pharmacology space, and not in a way that’s purely academic. Servier brought it to market in 1989 on a serotonin reuptake enhancement story that was basically the mirror image of SSRIs, and that framing lasted for a quarter century. Then in 2014, Gassaway and colleagues dropped the paper that upended the whole classification: tianeptine is a moderately potent, highly selective full mu-opioid receptor agonist, with a Ki of 383 nanomolar and an EC50 of 194 nanomolar for G-protein activation relative to DAMGO. The antidepressant behavior in rodent models is abolished in MOR knockouts and blocked by naloxone. That’s a decisive mechanistic reassignment, and it matters.

Here’s the thing that makes tianeptine genuinely interesting as a research object: if the primary antidepressant mechanism is MOR agonism, then we have an approved drug in 60 countries that validates opioid-based mood modulation at therapeutic doses. Thats not a trivial data point. The ALKS 5461 (buprenorphine/samidorphan) program tried to exploit exactly this biology and failed in phase 3, which actually makes tianeptine’s 60-country approval record more interesting, not less. Why does it work when the buprenorphine strategy didn’t? The downstream answer points at AMPA receptor trafficking and hippocampal synaptic plasticity, specifically stress-induced dendritic retraction reversal, which is a distinct mechanism from simple MOR analgesia and a legitimate research hook for stress-neuroplasticity biology.

Where we get cautious is on translational momentum. The abuse liability picture has gotten progressively worse. Multiple U.S. states have banned it, the FDA has issued import alerts and warning letters, and the overdose literature from emergency departments reflects a compound with real addiction and withdrawal properties. That regulatory drag limits the size of the serious human research community and suppresses evidence quality for the most interesting mechanistic questions. The existing evidence base is substantial for antidepressant efficacy, but most of it was generated in the pre-MOR-reclassification era, so the mechanistic interpretations are retrospectively awkward.

We think tianeptine earns its place in the library primarily as a probe compound for the MOR-mood axis and for stress-induced neuroplasticity research. The 2014 reclassification made it a legitimate reference standard for a question the field still doesn’t fully understand: what does endogenous opioid tone actually do to mood regulation, and how much of that is plasticity-mediated versus direct receptor activity? Thats a real question worth answering. What it isn’t is a novel compound or a compound with obvious translational upside right now. The abuse story is getting louder, not quieter, and that matters for what research programs it can anchor.

Novelty

35

Mechanism promise

55

In-category differentiation

45

Evidence quality

55

Translational signal

60

Research bench value

55

Rationale Tianeptine scores in the mid-range because the 2014 Gassaway reclassification as a full MOR agonist genuinely reopened mechanistic questions that had seemed settled, and the downstream AMPA trafficking and hippocampal plasticity work is real bench science. But the compound is nearly 55 years old, the European clinical literature is mature and somewhat insular, and the escalating abuse liability picture creates regulatory drag that limits translational momentum and suppresses meaningful score elevation on differentiation and novelty axes.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical tricyclic antidepressant with mu-opioid receptor agonism and glutamatergic neuroplasticity modulation

A dibenzothiazepine tricyclic derivative developed by Servier as a serotonin reuptake enhancer, subsequently reclassified as a moderately potent full mu-opioid receptor agonist with downstream effects on AMPA receptor trafficking, hippocampal synaptic plasticity, and stress-induced neuromorphological remodeling.

Abstract

Tianeptine is an atypical tricyclic antidepressant bearing a dibenzothiazepine nucleus and an aminoheptanoic acid side chain, first synthesized by the Science Union et Cie, Societe Francaise de Recherche Medicale in 1971 and brought to market in France in 1989 by Laboratoires Servier under the brand name Stablon. The compound is approved as an antidepressant in approximately 60 countries, predominantly in Europe, Asia, and Latin America, but is not approved by the United States Food and Drug Administration, Health Canada, or the Australian Therapeutic Goods Administration. Tianeptine was originally classified as a selective serotonin reuptake enhancer on the basis of early microdialysis studies demonstrating increased serotonin clearance from the synaptic cleft, a mechanism diametrically opposite to that of the selective serotonin reuptake inhibitors. This original mechanistic classification was substantially revised by the landmark 2014 report from Gassaway and colleagues, which demonstrated that tianeptine is a moderately potent but highly efficacious and selective full agonist at the mu-opioid receptor (MOR), with Ki of 383 nanomolar and EC50 of 194 nanomolar for G-protein activation relative to DAMGO, and negligible affinity at delta-opioid and kappa-opioid receptors [1]. Subsequent studies confirmed that the behavioral antidepressant effects of tianeptine in rodent forced swim test and tail suspension test models are abolished in mu-opioid receptor knockout mice and are blocked by the opioid antagonist naloxone, establishing the MOR as the primary pharmacological target for the antidepressant activity [2].

A second, mechanistically distinct axis of tianeptine pharmacology involves modulation of glutamatergic neurotransmission and synaptic plasticity. Tianeptine stabilizes surface AMPA receptor populations through a calcium/calmodulin-dependent protein kinase II (CaMKII) dependent mechanism that promotes the binding of the AMPA receptor auxiliary subunit stargazin with postsynaptic density protein 95 (PSD-95), thereby reducing AMPA receptor surface diffusion and restoring long-term potentiation in the hippocampus of stressed animals [3, 4]. Tianeptine prevents corticosterone-induced dispersal of AMPA receptors from the postsynaptic density and blocks stress-induced reductions in hippocampal dendritic arborization, spine density, and neurogenesis. These neuroplastic effects are observed at clinically relevant concentrations and are hypothesized to mediate the sustained antidepressant and anxiolytic efficacy that persists beyond the short plasma half-life of the parent compound.

Pharmacokinetics are characterized by near-complete oral bioavailability (approximately 99 percent), rapid absorption with time to peak plasma concentration of approximately one hour, high plasma protein binding (approximately 95 percent), a short elimination half-life for the parent compound of 2.5 to 3 hours necessitating three-times-daily dosing at the standard 12.5 mg dose, and hepatic metabolism predominantly through beta-oxidation (not cytochrome P450 enzymes) to the active metabolite MC5, which retains mu-opioid agonist activity with an EC50 of 545 nanomolar and has a longer elimination half-life of approximately 7.6 hours [5, 6]. The CYP-independent metabolism limits clinically significant drug-drug interactions relative to other antidepressant classes.

Clinical efficacy in major depressive disorder has been established in multiple randomized controlled trials comparing tianeptine with placebo, imipramine, amitriptyline, fluoxetine, paroxetine, and sertraline. A meta-analysis of five randomized controlled trials encompassing 1,348 patients found no significant difference between tianeptine and SSRIs on the Montgomery-Asberg Depression Rating Scale total score or responder rate [7]. Tianeptine demonstrates a tolerability advantage over classical tricyclic antidepressants, producing significantly fewer cardiovascular, anticholinergic, sedative, and weight-gain adverse events, and a tolerability profile broadly comparable to SSRIs with lower rates of sexual dysfunction [8].

The mu-opioid receptor agonism has introduced a substantial abuse liability signal, particularly in the United States where tianeptine has been marketed as an unregulated dietary supplement and sold at gas stations and convenience stores under brand names such as ZaZa and Tianna. At supratherapeutic doses (typically 10- to 100-fold above the clinical dose), tianeptine produces opioid-type euphoria, physical dependence, and a withdrawal syndrome clinically indistinguishable from classical opioid withdrawal [9]. The FDA has issued public warnings, and as of 2026, at least 15 United States states have scheduled or banned tianeptine [10]. Italy became the first European country to classify tianeptine as a controlled substance in 2020. This monograph reviews the chemistry, synthesis, and structural pharmacology of tianeptine; the dual mu-opioid and glutamatergic mechanisms in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across depressive, anxious, and comorbid indications; the sourcing, reconstitution, and handling considerations for laboratory work; the stack-interaction profile; the adverse-event and abuse-liability signal; and a comparative assessment of five antidepressant alternatives against tianeptine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1502Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Bronchogen

Our opinion on this compoundSingle-lab provenance

35/100

Interesting epigenetic mechanism claim anchored to single-consortium preclinical work with zero human trial data

Look, Bronchogen sits in a category that demands honest scrutiny: the Khavinson ultrashort peptide family, where the evidence has a consistent structural problem. The Saint Petersburg Institute of Bioregulation and Gerontology has produced decades of work on tissue-specific tetrapeptides, and Bronchogen (ADEL; H-Ala-Asp-Glu-Leu-OH) is their bronchopulmonary entry. The mechanism story is genuinely interesting on paper. Direct peptide-DNA binding leading to chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells is not a boring claim. Ki67 upregulation, Mcl-1 regulation, NOS-3 modulation, ciliated epithelial restoration in nitrogen dioxide-induced COPD rat models — the preclinical data is internally consistent and mechanistically coherent.

Here’s the thing, though: all of this comes from essentially one research consortium. Khavinson’s lab is both the discoverer and the sole replicator. That’s the same situation as Epitalon, Cardiogen, Cortagen, and the rest of the family. The epigenetic DNA-binding mechanism is compelling as a hypothesis but has not been independently validated outside that group. When a single institution controls both the original characterization and all subsequent replication, the evidence quality ceiling drops sharply regardless of how interesting the proposed biology is.

The differentiation picture is also weaker than it looks. Bronchogen shares the bronchopulmonary tissue-specificity claim with Chonluten (EDL tripeptide), which is the shorter sibling from the same lab. Two Khavinson bronchopulmonary peptides with overlapping claimed activities, both from a single source, neither with external replication — thats not head-to-head competition, that’s a redundancy problem. Against the broader respiratory-protective compound space, BPC-157 and GHK-Cu have multi-lab preclinical coverage, and NAC has decades of real clinical evidence in COPD. Bronchogen has none of that external support.

There is no published human clinical trial data. Zero. The Russian BAA registration represents dietary supplement classification, not clinical proof of efficacy. Pharmacokinetic data on the isolated synthetic ADEL tetrapeptide is absent; the PEPT1/PEPT2 intestinal transport hypothesis is reasonable for tetrapeptides as a class but has not been demonstrated specifically for this compound. Oral bioavailability is assumed rather than measured.

We think the epigenetic chromatin remodeling angle for ultrashort peptides is worth watching. If independent groups ever validate the Khavinson DNA-binding model, the whole family including Bronchogen gets significantly more interesting as a research tool. Right now, that validation hasnt happened. For an investigator working on bronchial epithelial biology or COPD models, Bronchogen is a plausible probe for a specific hypothesis, but you’re building on a literature base that hasn’t cleared the replication hurdle. That constraint is what keeps the score where it is.

Novelty

48

Mechanism promise

50

In-category differentiation

30

Evidence quality

22

Translational signal

20

Research bench value

30

Rationale Bronchogen shares the structural evidence problem of the entire Khavinson family: the Saint Petersburg Institute is both originator and sole replicator, producing an internally consistent but externally unvalidated literature. The DNA-chromatin remodeling mechanism is a genuinely interesting hypothesis, but no independent lab has confirmed it and no human clinical data exists, placing it firmly alongside Epitalon in the single-lab-only tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic bronchopulmonary tetrapeptide bioregulator with epigenetic gene-regulatory and anti-inflammatory activity targeting bronchial epithelium

A synthetic tetrapeptide (H-Ala-Asp-Glu-Leu-OH; ADEL) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with bronchopulmonary tissue-specific proliferative, anti-inflammatory, and epithelial-regenerative activity targeting bronchial epithelium, ciliated cell restoration, and respiratory mucosal barrier function.

Abstract

Bronchogen (H-Ala-Asp-Glu-Leu-OH; ADEL tetrapeptide; molecular formula C18H30N4O9; molecular weight 446.45 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the bronchopulmonary-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the respiratory system bioregulator within this peptide family. Bronchogen is structurally related to but distinct from the other Khavinson tetrapeptides that share the Ala-Glu-Asp tripeptide core (Cardiogen, Cortagen, Epithalon); the ADEL sequence carries a different arrangement of the acidic residues (Asp at position two, Glu at position three) and a hydrophobic leucine residue at the C-terminus, a configuration that determines bronchial tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Bronchogen, characterized through molecular modeling, cell culture, organotypic bronchial tissue studies, and animal models of obstructive lung disease, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA and with histone proteins, producing chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells [5, 6, 7]. The bronchopulmonary activity, characterized in organotypic lung tissue cultures from young and aged rats, human bronchial epithelial cell cultures across multiple passages, and nitrogen dioxide-induced chronic obstructive pulmonary disease (COPD) rat models, includes stimulation of bronchial epithelial cell proliferation and differentiation with upregulation of differentiation markers in aging cell cultures [8, 9], regulation of Ki67, Mcl-1, p53, CD79, and endothelial nitric oxide synthase (NOS-3) protein expression in human bronchial epithelium [5], restoration of normal ciliated epithelial architecture with reduction of goblet cell hyperplasia and squamous metaplasia in COPD models [10], normalization of proinflammatory cytokine profiles and neutrophilic inflammation in bronchoalveolar lavage fluid [10, 11], and enhancement of secretory immunoglobulin A and surfactant protein B production indicating recovery of respiratory mucosal barrier and surfactant function [11]. No formal pharmacokinetic studies have been published for Bronchogen as the isolated synthetic ADEL tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [12, 13]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Bronchogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Bronchogen; the discovery and development history within the Khavinson bioregulatory peptide program; the molecular pharmacology including peptide-DNA binding, histone interaction, and bronchial gene expression modulation; the pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology across bronchial, inflammatory, and aging cell models; the clinical evidence base (absent); sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five bronchopulmonary or respiratory-protective peptide candidates (Chonluten, GHK-Cu, BPC-157, Thymalin, N-acetylcysteine) against Bronchogen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1511Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Glutathione

Our opinion on this compoundResearch workhorse

33/100

Century-old redox infrastructure molecule; thoroughly characterized, poor exogenous pharmacology, real bench utility

Look, glutathione is one of the most important molecules in mammalian biology. That’s also exactly why it scores low here. When a compound’s mechanism fills entire textbook chapters and has been understood for decades, it’s not a research frontier. It’s infrastructure. Hopkins pulled it from yeast and blood in 1921. The gamma-glutamyl linkage was elucidated through the 1930s. The GPx, GST, and glutaredoxin frameworks were mapped systematically across the 1970s and 80s. The Nrf2-Keap1 regulatory axis that governs endogenous GSH synthesis is now itself a drug target with its own crowded literature. There’s not much left to discover about what glutathione does. That’s the honest position.

The bench value is what keeps this off the floor. The GSH/GSSG redox couple is a workhorse readout in any lab doing oxidative stress biology. Ellman’s reagent, HPLC quantification of thiol pools, fluorescent roGFP reporters: these are standard assays that make glutathione genuinely useful as a reference substrate and redox indicator. If you’re studying Nrf2 pathway modulation, or comparing antioxidant interventions in a hepatocyte model, GSH/GSSG ratios are central. That’s real bench utility, and we credit it accordingly.

But as a research target (as the compound you’d anchor a funded investigation around) the case is weak. The mechanism is solved. Differentiation is poor: NAC consistently outperforms direct GSH supplementation for raising intracellular thiol pools, because oral glutathione is hydrolyzed in the gut before meaningful absorption and the body regulates its own biosynthesis tightly through gamma-glutamylcysteine synthetase. There is literature on liposomal forms and S-acetyl-glutathione improving cellular delivery, but those are derivatives with their own research profiles; plain GSH gets credit for none of that here.

The clinical picture is scattered. Small trials span Parkinson’s disease, NAFLD, COPD, type 2 diabetes, and skin lightening. Some signals are real but modest and inconsistently replicated. None rise to the level of a compelling, replicated human outcome that would anchor a program. The IV use in acetaminophen hepatotoxicity is clinically valid, but NAC owns that indication and has for thirty years.

What we like: the bench utility in redox biology is genuine and not going away. What we don’t like: brilliant molecule, largely solved biology, poor exogenous pharmacology, no defining clinical signal, and multiple better alternatives for almost every application someone might cite. Thats the summary. We use it in assays. We dont build research programs around it.

Novelty

14

Mechanism promise

18

In-category differentiation

25

Evidence quality

55

Translational signal

45

Research bench value

62

Rationale Novelty and mechanism scores bottom out because glutathione’s biochemistry is textbook-complete across a century of literature; the compound earns a moderate bench_value credit for its indispensable role as a redox assay reference, but that is insufficient to offset near-zero novelty and weak differentiation against precursors like NAC.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous tripeptide thiol antioxidant and phase II conjugation cofactor

The principal low-molecular-weight thiol in mammalian cells, serving as the dominant intracellular antioxidant, electrophile conjugation substrate, and redox signaling mediator across virtually all aerobic tissues.

Abstract

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine; GSH) is a ubiquitous tripeptide thiol present in virtually all mammalian cells at intracellular concentrations of 1 to 10 millimolar, constituting the single most abundant non-protein sulfhydryl compound in animal tissues and the central node of cellular redox homeostasis. First isolated by Sir Frederick Gowland Hopkins in 1921 from yeast, blood, and muscle tissue and subsequently characterized as a gamma-linked glutamyl-cysteinyl-glycine tripeptide by Hopkins and colleagues over the following decade, glutathione occupies a singular position in biochemistry: it is simultaneously the principal intracellular reductant maintaining the thiol-disulfide balance of cytosolic and mitochondrial protein pools; the obligate cofactor for glutathione peroxidases (GPx1 through GPx8), glutathione S-transferases (GST alpha, mu, pi, theta, sigma, kappa, omega, and zeta classes), and glutaredoxins; and the substrate for phase II xenobiotic conjugation reactions that render electrophilic metabolites water-soluble for biliary and renal excretion. The reduced form (GSH) predominates under physiological conditions, typically exceeding the oxidized disulfide form (GSSG) by a ratio of 100:1 in the cytosol, with the GSH/GSSG redox couple establishing the electrochemical set point against which cellular redox-sensitive signaling cascades operate, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, NF-kappaB modulation, and apoptosis signal-regulating kinase 1 (ASK1) regulation.

Biosynthesis proceeds through two sequential ATP-dependent enzymatic steps: gamma-glutamylcysteine ligase (GCL, formerly gamma-glutamylcysteine synthetase) catalyzes the rate-limiting condensation of L-glutamate and L-cysteine via an atypical gamma-carboxyl peptide bond, and glutathione synthetase (GSS) subsequently ligates glycine to the gamma-glutamylcysteine dipeptide. Both enzymes are transcriptionally regulated by the Nrf2-Keap1-ARE (antioxidant response element) pathway, establishing a feedback loop in which oxidative or electrophilic stress induces Nrf2 nuclear translocation, upregulates GCL and GSS expression, and thereby increases glutathione synthesis capacity. Cysteine availability is typically the rate-limiting substrate for biosynthesis, a constraint that underwrites the therapeutic rationale for N-acetylcysteine (NAC) as an indirect glutathione precursor strategy.

The pharmacokinetics of exogenous glutathione are dominated by poor oral bioavailability. The intact tripeptide is a substrate for gamma-glutamyltransferase (GGT) at the intestinal brush border and for intraluminal peptidases, resulting in extensive presystemic hydrolysis. Early pharmacokinetic studies in humans reported negligible increases in plasma or erythrocyte glutathione after single oral doses of reduced glutathione. However, a landmark 2015 randomized, double-blind, placebo-controlled trial by Richie et al. demonstrated that chronic oral supplementation at 250 mg or 1,000 mg daily for six months produced significant, dose-dependent increases in glutathione stores in erythrocytes (up to 35 percent), plasma, lymphocytes, and buccal mucosal cells, with an associated twofold increase in natural killer cell cytotoxicity in the high-dose group. These findings, together with subsequent work on liposomal, sublingual, and S-acetyl glutathione delivery systems that partially circumvent presystemic hydrolysis, have rekindled interest in direct glutathione supplementation as a complement to the established precursor strategy.

Clinically, glutathione depletion has been documented in a broad spectrum of disease states characterized by chronic oxidative stress, including Parkinson disease (40 percent depletion in the substantia nigra at preclinical stages), nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, HIV/AIDS, cystic fibrosis, and age-related decline. Interventional evidence remains modest relative to the scope of the preclinical and epidemiological literature. In Parkinson disease, the Sechi et al. (1996) open-label study of intravenous glutathione (600 mg twice daily for 30 days) reported a 42 percent mean improvement in disability scores with effect persisting 2 to 4 months, but the Hauser et al. (2009) randomized, double-blind pilot trial of intravenous glutathione (1,400 mg three times weekly for 4 weeks) did not achieve statistical significance on the primary UPDRS endpoint, though a trend toward symptomatic improvement was noted. In hepatic applications, intravenous glutathione is used clinically in several jurisdictions as adjunctive therapy for drug-induced liver injury and for the potentiation of NAC in acetaminophen toxicity, where the glutathione-NAPQI conjugation pathway is the principal detoxification mechanism. In dermatology, oral and intravenous glutathione have been studied for skin lightening through inhibition of tyrosinase and melanin biosynthesis, with modest clinical evidence supporting efficacy at doses of 250 to 500 mg daily.

This monograph reviews the chemistry, biosynthesis, and compartmental distribution of glutathione; the enzymatic mechanisms of the glutathione-dependent antioxidant and conjugation systems; the pharmacokinetics and bioavailability considerations across oral, intravenous, liposomal, and sublingual routes; the preclinical pharmacology in models of neurodegeneration, hepatotoxicity, and inflammation; the clinical evidence base across neurological, hepatic, immunological, and dermatological indications; sourcing and quality verification considerations for research applications; reconstitution and handling; stack interactions with other redox-active compounds and pharmaceuticals; an adverse-event and safety profile; and a comparative assessment of five alternative glutathione-elevating strategies (N-acetylcysteine, S-acetyl-L-glutathione, liposomal glutathione, alpha-lipoic acid, and whey protein isolate) against reduced glutathione on five competency standards (bioavailability, effect size on tissue glutathione stores, clinical evidence breadth, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1517Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Masteron

Our opinion on this compoundEstablished workhorse

25/100

Historically approved DHT-derived AAS displaced by superior agents, offering minimal modern research priority

Look, Masteron is one of those compounds where the story is almost entirely historical. Drostanolone propionate was synthesized at Syntex in 1959, got FDA approval for palliative breast cancer treatment in 1961, and spent roughly two decades as a legitimate oncology agent before tamoxifen made it essentially redundant. Thats the arc in a sentence.

The chemistry is genuinely interesting from a structure-activity standpoint and we want to be fair to it. The 2-alpha-methyl substitution on the DHT backbone confers resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism in skeletal muscle, which is why drostanolone retains measurable anabolic activity where unmodified DHT is rapidly inactivated. The compound also cant be aromatized, so you get clean AR agonism without estrogenic conversion, which was actually the pharmacologically relevant feature for estrogen-sensitive postmenopausal mammary carcinoma. That’s an elegant exploitation of a known metabolic vulnerability. The problem is that elegant and novel are not the same thing. This mechanism has been picked apart for 65 years. There is nothing left to discover about how drostanolone binds AR.

The evidence base for the registered indication is real but dated in ways that matter. The breast cancer trials from the late 1960s and early 1970s were small by modern standards, variably blinded, and used response criteria that don’t map to contemporary oncology endpoints. The compound worked in context. But that clinical chapter closed decisively when SERMs and aromatase inhibitors arrived, and there is no active development program in any indication today. What remains in the literature are observational studies, narrow androgen physiology investigations, and performance-context reports that don’t constitute translatable bench research.

As an AR agonist probe, testosterone and DHT are more accessible reference compounds with deeper characterization literature. If selective AR modulation with tissue specificity is the question, the SARM literature has structurally and pharmacologically surpassed anything a 1959 androstane derivative can offer. The differentiation case for drostanolone in a modern research program depends entirely on the 3-alpha-HSD resistance story, which is pharmacologically legitimate but not under active investigation anywhere serious we can identify.

Scheduling is worth noting: drostanolone is Schedule III in the United States under the Anabolic Steroid Control Act. That adds real regulatory friction to a research protocol without any offsetting scientific upside. Hepatotoxicity is minimal relative to 17-alpha-alkylated AAS given the absence of that modification, but the scheduling status imposes compliance overhead that has to be weighed against what you’re actually going to learn. Honestly, the answer here is: not much that isn’t already known. Worth understanding for DHT analog SAR context, not a priority for active research time in 2026.

Novelty

15

Mechanism promise

22

In-category differentiation

28

Evidence quality

42

Translational signal

22

Research bench value

28

Rationale Drostanolone is a 65-year-old androstane steroid whose only registered indication was rendered obsolete by tamoxifen and aromatase inhibitors; the structural features are pharmacologically coherent but exhaustively characterized, and there is no active development program or emerging indication to drive research interest in 2026. Schedule III cap (75) does not bind since raw score falls well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic anabolic-androgenic steroid; 2-alpha-methyl-5-alpha-dihydrotestosterone 17-beta-propionate ester (androstane-derived androgen receptor agonist)

A non-aromatizable, DHT-derived androgen receptor agonist originally developed by Syntex and approved for palliative treatment of advanced breast cancer in postmenopausal women, distinguished from other anabolic-androgenic steroids by its 2-alpha-methyl substitution conferring resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism and a favorable anabolic-to-androgenic activity ratio.

Abstract

Masteron is the principal trade name for drostanolone propionate, the 17-beta-propionate ester of 2-alpha-methyl-5-alpha-dihydrotestosterone (2-alpha-methyl-DHT), a synthetic androstane steroid first described in 1959 and introduced to clinical medicine in 1961 following United States Food and Drug Administration approval for the palliative treatment of advanced, inoperable, androgen-responsive mammary carcinoma in postmenopausal women. The compound was developed by Syntex Corporation, licensed to Eli Lilly and Company, and marketed in the United States as Drolban and in European and other international markets as Masteril, Masteron, and Permastril. Drostanolone is a direct structural derivative of dihydrotestosterone (DHT) bearing a methyl group at the carbon-2 alpha position, a modification that confers two pharmacologically consequential properties: resistance to metabolic inactivation by 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD) in skeletal muscle tissue, resulting in enhanced anabolic potency relative to the parent DHT molecule; and retention of the intrinsic non-aromatizability of the 5-alpha-reduced steroid nucleus, ensuring that the compound cannot be converted to estrogenic metabolites by the aromatase enzyme complex. As an androgen receptor (AR) agonist, drostanolone binds the AR with high affinity and initiates the canonical genomic androgen signaling cascade, including nuclear translocation, receptor dimerization, coactivator recruitment, and transcriptional activation of androgen-responsive genes governing protein synthesis, nitrogen retention, and musculoskeletal anabolism.

The clinical pharmacology of drostanolone propionate is defined by its intramuscular depot formulation. The propionate ester is hydrolyzed in vivo by tissue and plasma esterases to release the active drostanolone moiety, with an elimination half-life of approximately 2 to 3 days following intramuscular injection. The compound is not orally bioavailable owing to the absence of a 17-alpha-alkyl group; this same structural feature eliminates the hepatotoxicity risk associated with oral anabolic-androgenic steroids such as methyltestosterone and oxymetholone. Protein binding is high, predominantly to sex hormone-binding globulin (SHBG) and albumin. Metabolism proceeds through reduction and conjugation pathways; the principal urinary metabolites include 2-alpha-methyl-5-alpha-androstan-3-alpha-ol-17-one and its glucuronide and sulfate conjugates, which serve as the analytical targets for anti-doping detection.

The registered clinical indication was the palliation of advanced breast cancer in women who were more than one year but less than five years postmenopausal, with documented androgen-responsive or estrogen-receptor-positive disease that had progressed following initial endocrine therapies. Early clinical trials reported objective response rates of approximately 20 to 30 percent, including partial tumor regression and symptomatic palliation. The antitumor mechanism was attributed to competitive androgen receptor-mediated antagonism of estrogen-dependent tumor proliferation, with additional evidence suggesting inhibition of prolactin receptor expression and downregulation of estrogen receptor density in mammary tissue. The clinical application of drostanolone propionate and other androgenic agents in breast cancer was largely superseded in the 1970s and 1980s by the introduction of selective estrogen receptor modulators (tamoxifen) and subsequently by aromatase inhibitors (anastrozole, letrozole, exemestane), which offered comparable or superior efficacy with substantially reduced virilization burden. Drostanolone propionate is no longer marketed in any jurisdiction for the breast cancer indication.

The compound persists in contemporary relevance principally through its widespread non-medical use in performance and physique enhancement contexts, where it is valued for its non-aromatizable androgenic profile, its favorable anabolic-to-androgenic ratio, and its relatively mild side-effect burden compared to other injectable anabolic-androgenic steroids. Drostanolone is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of anabolic agents (S1) and is detectable in urine for up to 3 to 4 weeks following administration through gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of phase II metabolite conjugates. This monograph reviews the chemistry, synthesis, and stereochemistry of drostanolone propionate; the androgen receptor-mediated mechanism of action including antiestrogenic activity in mammary tissue; the pharmacokinetic profile of the propionate and enanthate ester formulations; the preclinical pharmacology; the clinical evidence base in breast cancer and related indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions with other androgenic and ancillary compounds; adverse events and safety signals; and a comparative assessment of five alternative androgenic or antiestrogenic agents against drostanolone propionate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1550Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
PPAP-HCl

Our opinion on this compoundNiche research probe

45/100

Niche Knoll-school catecholaminergic probe with fresh TAAR1 data but thin independent replication

PPAP-HCl sits in an unusual corner of catecholaminergic pharmacology, which is exactly what makes it interesting to a small but serious group of investigators. Jozsef Knoll’s group at Semmelweis synthesized this compound in the late 1980s as a deliberate surgical operation on selegiline: keep the catecholaminergic enhancer activity, strip the MAO-B inhibition. The idea was to isolate what Knoll called the enhancer effect from the messier polypharmacology of the parent compound, and they largely succeeded.

What we find genuinely compelling here is the mechanism story, which has gotten more interesting with time rather than less. The original catecholaminergic activity enhancer concept, potentiating impulse-dependent dopamine and norepinephrine release from vesicles without triggering the uncontrolled efflux characteristic of amphetamine, was already novel when Knoll formally described it in 1992. The compound doesn’t block autoreceptors, doesn’t inhibit MAO, and doesn’t operate like a classical reuptake inhibitor. It was a genuinely different way of thinking about catecholaminergic modulation, and that distinctiveness still holds up.

The 2025 pharmacological characterization adds another layer worth paying attention to. PPAP turns out to be a potent DAT reuptake inhibitor at an IC50 of 57.5 nM and a NET inhibitor at 571 nM, which means the pure-enhancer framing from the original Knoll papers was incomplete. Now you have a compound with dual mechanism: enhancer activity plus reuptake inhibition, and putative TAAR1 agonism as a possible mechanistic spine for both. TAAR1 is a genuinely active research area right now, and PPAP offers investigators a structurally distinct probe that differs from the typical TAAR1 ligands in the literature. Thats a real asset for anyone trying to dissect the receptor’s role in impulse-dependent dopamine dynamics.

Here’s where we have to be honest about the limitations. The evidence base is thin in a specific way: it’s not that there are no data, it’s that Knoll’s Semmelweis group generated most of it across a publishing window that closed around 2005. Meaningful independent replication is limited. There are no human clinical trials to speak of. PPAP has never moved through the clinic, and without a bench-to-human arrow it’s hard to know what effect size actually looks like in people. The 2025 DAT/NET characterization comes from outside Semmelweis, which helps, but one fresh paper doesn’t change the structural evidence problem.

We think this compound has real utility as a research tool for anyone working on TAAR1 biology or the CAE mechanism specifically. It’s a structurally clean, chirally defined probe with a long preclinical track record and a freshly updated mechanistic profile. For that specific research context it earns shelf space. But it’s not a compound with broad crossover appeal, and the evidence base doesn’t justify treating it as anything beyond a niche investigational tool at this stage.

Novelty

48

Mechanism promise

65

In-category differentiation

48

Evidence quality

28

Translational signal

18

Research bench value

55

Rationale Evidence base is primarily the Knoll group at Semmelweis across a 15-20 year window now mostly closed, with no independent clinical development; the dual CAE-plus-DAT-inhibition mechanism and 2025 TAAR1 characterization give it genuine bench value in catecholaminergic research, but evidence quality and a complete absence of human data drag the overall down significantly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Catecholaminergic activity enhancer (CAE) and dopamine transporter reuptake inhibitor derived from the phenylalkylamine/substituted amphetamine scaffold

A selegiline-derived catecholaminergic activity enhancer that potentiates impulse-dependent dopamine and norepinephrine release in the brain without monoamine oxidase inhibition, distinguished from classical psychostimulants by a broad therapeutic dose window and absence of uncontrolled monoamine efflux.

Abstract

PPAP-HCl, the hydrochloride salt of (-)-(R)-1-phenyl-2-propylaminopentane, is an experimental catecholaminergic activity enhancer (CAE) compound originally synthesized by Jozsef Knoll and colleagues at Semmelweis University in Budapest in the late 1980s as a structural derivative of selegiline (L-deprenyl) designed to retain the catecholaminergic enhancer activity of the parent compound while eliminating its monoamine oxidase (MAO) inhibitory property. The compound occupies a mechanistically distinct position in the catecholaminergic pharmacology space: at low-to-moderate concentrations, PPAP potentiates the impulse-propagation-mediated (action-potential-dependent) release of dopamine and norepinephrine from catecholaminergic nerve terminals without producing the uncontrolled, impulse-independent monoamine efflux characteristic of amphetamine and methamphetamine. This “enhancer” mechanism, first formally described by Knoll in 1992 and subsequently elaborated in a series of publications through 2005, operates independently of MAO inhibition, presynaptic autoreceptor blockade, and classical reuptake inhibition, and instead potentiates the vesicular exocytotic release event coupled to the arriving action potential. Recent pharmacological characterization reported in 2025 has expanded the mechanistic profile by demonstrating that PPAP also acts as a potent dopamine transporter (DAT) reuptake inhibitor with an IC50 of 57.5 nM, a norepinephrine transporter (NET) inhibitor at 571 nM, and a weak serotonin transporter (SERT) inhibitor at 19,000 nM, placing it in a dual-mechanism category that combines enhancer activity with catecholamine reuptake inhibition. Additional evidence suggests that PPAP and related synthetic enhancer compounds may exert their catecholaminergic effects through agonism at trace amine-associated receptor 1 (TAAR1), an intracellular G-protein-coupled receptor that modulates vesicular dopamine release through protein kinase C (PKC)-mediated phosphorylation of exocytotic machinery.

In preclinical behavioral pharmacology, PPAP facilitates learning and retention in shuttle-box avoidance paradigms, potently antagonizes tetrabenazine-induced behavioral depression, reduces immobility in the forced swimming test, and increases locomotor activity across a broad dose range (2 to 50 mg/kg in rodents) without the narrow therapeutic window and stereotypy induction that characterize amphetamine-class stimulants. The therapeutic index in animal models exceeds that of amphetamine. Structure-activity relationship studies identified the (R)-enantiomer as the pharmacologically active form, while the racemic mixture (designated MK-306) retains partial activity. PPAP served as the reference catecholaminergic activity enhancer compound in the Knoll laboratory and led directly to the development of the more potent and serotonergically active successor compound BPAP [(-)1-(benzofuran-2-yl)-2-propylaminopentane] in 1999. PPAP has been proposed as a candidate for clinical development in depression, attention deficit hyperactivity disorder (ADHD), and Alzheimer’s disease, though no human clinical trials have been completed or published. The compound is not approved by any regulatory authority for therapeutic use and is available exclusively as a research-grade preparation. This monograph reviews the chemistry, synthesis, and stereochemistry of PPAP-HCl; the dual enhancer and reuptake-inhibitor pharmacology; the preclinical behavioral and neurochemical evidence base; the comparative assessment of five catecholaminergic and monoaminergic enhancer or stimulant candidates against PPAP on five competency standards; and the sourcing, reconstitution, and handling considerations for laboratory work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1528Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026

←Previous Page

1 … 13 14 15 16 17 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.